Bayer HealthCare is extending the scope of its collaboration with the Broad Institute of MIT and Harvard to include cardiovascular genomics and drug discovery.
The drugs giant has been working alongside the Broad Institute for two years within the oncology field, and has now formed a strategic alliance to use human genetics as the basis for new cardiovascular therapies.
The partners will collaborate on genetic discovery, target validation and drug discovery activities under the direction of a joint steering committee and a joint research committee.
Further terms, including financial details, were not disclosed.
